U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807281) titled 'A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema' on Jan. 29.
Brief Summary: This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Study Start Date: Nov. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: ...